Working… Menu

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00213070
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : September 21, 2006
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd.

Brief Summary:
The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: Miglitol Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

Drug Information available for: Miglitol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type2 diabetes
  • Criteria of postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

  • Type1 diabetes
  • Patients with antidiabetic drugs
  • The other exclusion criteria are met

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00213070

Layout table for location information
Aichi, Japan
Chiba, Japan
Fukuoka, Japan
Gifu, Japan
Gunma, Japan
Hokkaido, Japan
Ibaraki, Japan
Kagoshima, Japan
Kanagawa, Japan
Kumamoto, Japan
Miyazaki, Japan
Oita, Japan
Okinawa, Japan
Saitama, Japan
Shiga, Japan
Tokyo, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Layout table for investigator information
Study Director: Clinical Promotion Group Sanwa Kagaku Kenkyusho Co., Ltd.
Layout table for additonal information Identifier: NCT00213070    
Other Study ID Numbers: MG1005
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: September 21, 2006
Last Verified: September 2006
Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpha-glucosidase inhibitor,Insulin
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs
Glycoside Hydrolase Inhibitors